A Study of MK-1084 in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
Phase 1
58
about 8 months
18–80
3 sites in AZ, FL, TX
What this study is about
This trial is testing how MK-1084 affects the body over time. Researchers are measuring MK-1084 levels to understand its behavior. They also want to assess the safety of MK-1084 in people with liver problems and determine if they can tolerate it.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take MK-1084
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Apparent Clearance (CL/F) of Calderasib, Apparent Terminal Half-life (t1/2) of Calderasib, Maximum Observed Drug Concentration (Cmax) of Calderasib, Time to Maximum Observed Drug Concentration (Tmax) of Calderasib
Secondary: Number of Participants Who Discontinue Study Due to an AE, Number of Participants Who Experience an Adverse Event (AE)